BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 12153595)

  • 1. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
    Kaltsas GA; Mukherjee JJ; Isidori A; Kola B; Plowman PN; Monson JP; Grossman AB; Besser GM
    Clin Endocrinol (Oxf); 2002 Aug; 57(2):169-83. PubMed ID: 12153595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
    Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
    Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors.
    Bajetta E; Rimassa L; Carnaghi C; Seregni E; Ferrari L; Di Bartolomeo M; Regalia E; Cassata A; Procopio G; Mariani L
    Cancer; 1998 Jul; 83(2):372-8. PubMed ID: 9669822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response.
    Buscombe JR; Cwikla JB; Caplin ME; Hilson AJ
    Nucl Med Commun; 2005 Nov; 26(11):969-76. PubMed ID: 16208174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for neuroendocrine tumors: the Beatson Oncology Centre experience.
    Hatton MQ; Reed NS
    Clin Oncol (R Coll Radiol); 1997; 9(6):385-9. PubMed ID: 9448967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
    Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors.
    Kaltsas GA; Mukherjee JJ; Plowman PN; Monson JP; Grossman AB; Besser GM
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4233-8. PubMed ID: 9851756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
    Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
    J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors.
    Saltz L; Kemeny N; Schwartz G; Kelsen D
    Cancer; 1994 Aug; 74(3):958-61. PubMed ID: 8039124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
    Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
    Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association.
    Richards F; Case LD; White DR; Muss HB; Spurr CL; Jackson DV; Cooper MR; Zekan P; Cruz J; Stuart JJ
    J Clin Oncol; 1986 Apr; 4(4):565-70. PubMed ID: 3514806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours.
    Dilz LM; Denecke T; Steffen IG; Prasad V; von Weikersthal LF; Pape UF; Wiedenmann B; Pavel M
    Eur J Cancer; 2015 Jul; 51(10):1253-62. PubMed ID: 25935542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of dihydropyrimidine-dehydrogenase and thymidylate-synthase in patients with pancreatic neuroendocrine neoplasms treated with 5-FU-based chemotherapy.
    Krug S; Boch M; Nimphius W; Gress TM; Michl P; Rinke A
    Pancreatology; 2017; 17(1):139-145. PubMed ID: 28027897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
    Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
    Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group.
    Di Bartolomeo M; Bajetta E; Bochicchio AM; Carnaghi C; Somma L; Mazzaferro V; Visini M; Gebbia V; Tumolo S; Ballatore P
    Ann Oncol; 1995 Jan; 6(1):77-9. PubMed ID: 7710986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
    Oberg K
    Ann Oncol; 2001; 12 Suppl 2():S111-4. PubMed ID: 11762335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience.
    Kong G; Johnston V; Ramdave S; Lau E; Rischin D; Hicks RJ
    Cancer Biother Radiopharm; 2009 Oct; 24(5):527-33. PubMed ID: 19877882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.
    Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R
    Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.